One of the major obstacles in human epidermal growth factor receptor (HER)-2/neu-specific trastuzumab immunotherapy of HER2/neu-positive breast cancer is the development of trastuzumab resistance, warranting the search for other therapeutic strategies. Although dendritic cell (DC) vaccines have been extensively applied in clinical trials for cancer treatment, the vaccination efficacy is still limited, mostly because DC vaccines are not sufficient to break tumor-associated antigen-specific self-immune tolerance in cancer patients. P30 (FNNFTVSFWLRVPKVSASHLE) derived from tetanus toxin is a universally potent CD4 þ T helper epitope capable of enhancing CD8 þ cytotoxic T-lymphocyte (CTL) responses. In this study, we constructed two recombinant adenoviral vectors (AdVs), AdV OVA-P30 and AdV HER2/neu-P30 , expressing ovalbumin (OVA)-P30 and HER2/neu-P30. In order to enhance DC vaccine efficacy, we transfected mouse bone marrow (BM)-derived DCs with AdV OVA-P30 and AdV HER2/neu-P30 to generate engineered DC OVA-P30 and DC HER2/neu-P30 vaccines, respectively. We, then, compared CD4 þ and CD8 þ T-cell responses and antitumor immunity derived from DC OVA-P30 and DC HER2/neu-P30 vaccination in wild-type C57BL/6 and transgenic FVBneuN mice, respectively. We demonstrate that engineered DC OVA-P30 vaccine stimulates more efficient CD4 þ and CD8 þ T-cell responses than DC OVA in C57BL/6 mice. Interestingly, the increased DC OVA-P30 -induced CTL responses are mainly contributed by enhanced CD4 þ T-cell-stimulated CTL proliferation. We show that DC OVA-P30 vaccine also stimulates more efficient therapeutic immunity against OVA-expressing BL6-10 OVA melanoma than DC OVA in C57BL/6 mice. In addition, we demonstrate that DC HER2/neu-P30 vaccine stimulates more efficient CD4 þ and CD8 þ T-cell responses and protective immunity against HER2/neu-expressing Tg1-1 breast cancer than DC HER2/neu in transgenic FVBneuN mice with HER2/neu-specific self-immune tolerance. Therefore, the engineered DC HER2/neu-P30 vaccine may provide a new immunotherapy alternative for women with HER2/neu þ breast cancer, especially for trastuzumab-resistant HER2/neu þ breast cancer patients.
INTRODUCTION
Conventional cancer therapies including surgery, radiation therapy and chemotherapy have demonstrated a considerable clinical success over the past few years. However, cancer-free survival is not always accomplished. For example, surgery and radiation therapy are quite effective in treatment of localized tumors, but they often have only a palliative role in treatment of disseminated diseases. Chemotherapy remains the treatment modality of choice, but severe toxic side effects often limit its use. The identification of tumor-associated antigens and tumor-specific T-cell responses, in cancer patients, has led to the development of immunotherapies aimed at augmenting antitumor immune responses.
Breast cancer is the most common cancer among women in the Western world. The proto-oncogene human epidermal growth factor receptor (HER)-2, also called HER2/neu, with 80% sequence homology to the rat neu gene-coded protein neu, originally detected on rat neuroblastoma cells, 1 is a tyrosine kinase receptor, belonging to the epidermal growth factor receptor family. 2, 3 The HER2/neu protein is over-expressed in about 20% cases of breast cancer.
2 HER2/neu has become an attractive tumor-associated antigen (TAA), because (i) it is selectively over-expressed in malignant cells and (ii) the immune responses to HER2/neu are frequently found in patients with HER2/neu-positive breast cancer, [4] [5] [6] indicating that the self tolerance to HER2/neu can be broken in humans. Although overexpression of HER2/neu is often associated with poor prognosis, 7 it permits novel therapies directed against HER2/neu, of which the humanized monoclonal antibody (Ab) trastuzumab is possibly the best known. 9 months. 9 However, most women sooner or later develop resistance against trastuzumab, 10, 11 warranting the search for other therapeutic strategies. 12 
CD8
þ cytotoxic T lymphocytes (CTLs) have an important role in host defense against viruses, intracellular bacteria and tumors. [13] [14] [15] [16] [17] 
CD4
þ helper T (Th) cells are required for CTL responses and memory CTL development. 18, 19 It was previously demonstrated that high-affinity CD4
þ Th cell epitope induced dendritic cell (DC) polarization, leading to increased CTL responses. 20 It has been recently demonstrated that HER2/neu-and ovalbumin (OVA)-specific DNA vaccines containing potent Th epitope P30, derived from tetanus toxin, induced enhanced CTL responses by breaking self-immune tolerance in transgenic mouse mammary tumor virus (MMTV)-c-neu and rat insulin promoter-mOVA mice, respectively. 21, 22 DCs are the most potent antigen-presenting cells in initiating antitumor immunity by presenting tumor-associated antigens to T cells and stimulating tumor-specific CTL responses. 23 DC vaccines have been extensively applied in experimental animal models and clinical trials for evaluation of antitumor immunity. 24, 25 In general, the efficacy of DC-mediated cancer vaccine is still limited, mostly because DC vaccines are not sufficient to break self-immune tolerance and suppressive tumor microenvironment. 24 In addition, antitumor CD4
þ T-cell responses are impaired in animal tumor models [26] [27] [28] [29] and in cancer patients, 30, 31 leading to suboptimal antitumor CTL responses. For these reasons, development of DC vaccines capable of inducing efficient CTL responses becomes a major goal in the field of tumor immunotherapy. CD4 þ T cells have potential to influence multiple aspects of CTL responses. [32] [33] [34] [35] [36] We have previously shown that HER2/neu-specific DC vaccine stimulated more efficient HER2/neu-specific CTL responses and antitumor immunity than DNA vaccine. 37, 38 Recently, we have demonstrated that DC vaccine-stimulated CTL responses were derived not only from the stimulation of CD4 þ T-cell-licensed DCs, but also from the stimulation of DC-primed CD4 þ T cells with acquired DC's peptide/MHC-I complexes by trogocytosis. 39 Therefore, we assume that DC vaccine containing the potent CD4 þ Th epitope P30 may stimulate enhanced CD4 þ T-cell responses, leading to more efficient HER2/neu-specific CTL responses and immunity against HER2/neu-positive breast cancer.
In this study, we constructed two recombinant adenoviral vectors (AdVs), AdV OVA-P30 and AdV HER2/neu-P30 , expressing OVA-P30 and HER2/neu-P30, respectively. We transfected mouse BMderived DCs with AdV OVA-P30 and AdV HER2/neu-P30 in order to generate engineered DC OVA-P30 and DC HER2/neu-P30 vaccines. We then compared OVA-and HER2/neu-specific CTL responses and antitumor immunity stimulated by DC OVA-P30 and DC HER2/neu-P30 vaccination in wild-type C57BL/6 and transgenic FVBneuN mice, respectively.
MATERIALS AND METHODS

Reagents, cell lines and animals
The biotin-labeled Abs specific for CD11c, CD80, Ia b and Ia q , and fluorescein isothiocyanate (FITC)-or phycoerythrin (PE)-labeled Abs specific for CD4, CD8 and CD44 were obtained from PharMingen Canada (Mississauga, ON, Canada). The anti-OVA Ab was obtained from Sigma (Oakville, ON, Canada). The anti-rat HER2/neu Ab was obtained from Cedarlane (Burlington, ON, Canada). The PE-labeled H-2K b /OVA 257-264 tetramer was obtained from Beckman Coulter (San Diego, CA, USA). The highly lung metastatic OVA-expressing B16 melanoma cell line BL6-10 OVA was generated in our laboratory. 40 The mouse breast cancer cell line Tg1-1 (H-2K q ) expressing rat HER2/neu was derived from a spontaneous breast cancer in FVBneuN mice. 37, 38 Female wild-type C57BL/6 (H-2K b ) mice and transgenic CD11c-diphtheria toxin receptor (DTR) (H-2K b ) and FVB/N-Tg(MMTVneu)202Mul/J (FVBneuN) (H-2K q ) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All animal experiments were carried out in accordance to the Canadian Council for Animal Care guidelines.
Construction of P30-bearing recombinant adenovirus AdV and AdV HER2/neu-P30
The pAc-Neo-OVA plasmid was kindly provided by Dr M Bevan, University of Washington (Seattle, WA, USA). The pshuttle-cytomegalovirus (CMV)-HER2/neu plasmid was previously constructed in our laboratory. 38 OVA-P30 and HER2/neu-P30 cDNA were further generated by inserting the DNA sequence encoding the promiscuous Th epitope P30 (FNNFTVSFWLRVPKVSASHLE) into OVA and HER2/neu cDNA by overlapextension-PCR mutagenesis technique, respectively. The OVA-P30 and HER2/neu-P30 cDNA were subcloned into plasmid pshuttle-CMV at BglII and SalI, and KpnI and HindIII sites, respectively. The PmeI-digested pshuttle-CMV-OVA-P30 or pshuttle-CMV-HER2/neu-P30 was then transformed into BJ5183 Escherichia coli cells containing pAdEasy-1 backbone vector for homologous recombination. Recombinant adenoviral plasmids pAdEasy-1-pshuttle-CMV-OVA-P30 (pAd-OVA-P30) and pAdEasy-1-pshuttle-CMV-HER2/neu-P30 (pAd-HER2/neu-P30) were digested with PacI, and subsequently transfected into 293 cells using Lipofectamine2000 to generate recombinant adenoviruses AdV 
Assessment of CD4
þ and CD8 þ T-cell responses by flow cytometry . The second type of animal study was designed to evaluate therapeutic antitumor immunity. The C57BL/6 mice (eight mice per group) were i.v. injected with BL6-10 OVA tumor cells (0.3 Â 10 6 cells per mouse). Three days after tumor challenge, the BL6-10 OVA -bearing C57BL/6 mice were i.v. treated with DC OVA-P30 or DC OVA vaccine (2 Â 10 6 cells per mouse). All of the above mice were killed 3 weeks after tumor challenge, and the lung metastatic tumor colonies were counted in a blind fashion. Metastases on freshly isolated lungs appeared as discrete black foci for BL6-10 OVA tumor and white foci for Tg1-1 tumor. Metastatic foci too numerous to count were assigned an arbitrary value of 4300. 42 
Statistical analyses
Statistical analyses were performed using the Student's t-test or the MannWhitney U test to compare variables from different groups. A value of Po0.05 was considered significant. þ and CD8 þ T-cell responses were significantly stronger than DC OVA vaccination (Po0.05) (Figures 1c and d) .
RESULTS
Engineered
Increased DTR-DC OVA-P30 -induced CTL responses are contributed by enhanced CD4 þ T-cell-stimulated CTL proliferation
As primed CD4 þ T cells are capable of stimulating CTL responses, 39 we further examined whether DC OVA-P30 -induced enhanced responses of CD4 þ T cells contribute to DC OVA-P30 -induced enhanced CTL responses. We performed a novel immunization protocol using DTR-DC OVA-P30 and DTR-DC OVA vaccines as described above in the Materials and methods section, which enabled us to separately assess CTL responses derived from primed CD4 þ T cells and licensed DTR-DC OVA-P30 . 39 We demonstrated that DTR-DC OVA-P30 stimulated 9.23% OVAspecific CTL responses, which were significantly stronger than 6.12% OVA-specific CTL responses seen in DTR-DC OVA -immunized mice (Po0.05) (Figure 2 ). Interestingly, we observed that the OVAspecific CTL responses (6.36%) detected in group of DTR-DC OVA-P30 -immunized mice with DT treatment (primed CD4 þ T-cell group) were significantly stronger than the OVA-specific CTL responses (3.89%), seen in group of DTR-DC OVA-P30 -immunized mice with DT treatment (Po0.05), whereas the OVA-specific CTL responses seen in DTR-DC OVA-P30 -and DTR-DC OVA -immunized mice with anti-CD4 Ab treatment (licensed DC group) remained similar ( Figure 2 ), indicating that increased DTR-DC OVA-P30 -induced CTL responses is mainly contributed by enhanced CD4 þ T-cellstimulated CTL proliferation.
Engineered DC OVA-P30 vaccine stimulates potent immunity against OVA-expressing BL6-10 OVA tumor in C57BL/6 mice To assess their stimulatory effect on antitumor immunity, we vaccinated C57BL/6 mice with DC OVA-P30 or DC OVA, and subsequently analyzed preventive and therapeutic antitumor immunity by challenging the mice with OVA-expressing BL6-10 OVA tumor cells post-and pre-immunization, respectively. We demonstrated that DC OVA-P30 or DC OVA immunization induced complete immune protection against BL6-10 OVA tumor cell challenge post immunization (Figure 3a) . When therapeutic antitumor immunity was examined, we observed that the mean number (25 black tumor colonies per lung) of metastatic tumor colonies, in the lungs of mice immunized with DC OVA-P30, was significantly smaller compared with the mice (137 black tumor colonies per lung) immunized with DC OVA (Po0.05), although all immunized mice were still bearing lung metastatic tumor colonies (Figure 3b) , indicating that DC OVA-P30 stimulates stronger therapeutic immunity against pre-existed 3-dayestablished BL6-10 OVA tumor colonies in the lungs than DC OVA vaccination.
Engineered DC HER2/neu-P30 vaccine stimulates enhanced HER2/neu-specific CTL responses We constructed a recombinant adenovirus (AdV HER2/neu-P30 ) expressing HER2/neu-P30 containing the promiscuous Th epitope P30 (FNNFTVSFWLRVPKVSASHLE) (Figure 4a ). We transfected BMderived DCs with AdV HER2/neu-P30 in order to generate engineered DC HER2/neu-P30 vaccine. We demonstrated that, similar to BMderived mature DCs, DC HER2/neu-P30 expressed DC marker CD11c and DC maturation markers CD80 and Ia q (Figure 4b ), indicating that they are mature DCs. In addition, 59.4% of DC HER2/neu-P30 expressed transgene HER2/neu (Figure 4b ). To assess their stimulatory effect on T-cell responses, we vaccinated transgenic FVBneuN mice with DC HER2/neu-P30 or DC HER2/neu , and subsequently analyzed CD4 þ or CD8 þ T-cell responses using FITC-conjugated anti-CD44 and PE-conjugated anti-CD4 or anti-CD8 Ab by flow cytometry. We demonstrated that DC HER2/neu-P30 -stimulated CD4 þ and CD8
þ T-cell responses were significantly stronger than DC HER2/neu (Po0.05) (Figures 4c and d) . (Figure 5c ). However, the mean number (16 white tumor colonies per lung) of metastatic tumor colonies in lungs of mice immunized with DC HER2/neu-P30 was significantly smaller than in the lungs of mice (144 white tumor colonies per lung) immunized with DC HER2/neu (Po0.05). The representation of white tumor colonies in the lung tissues was also confirmed by histopathologic study on the mouse lung sections (Figure 5d ). Our data indicate that DC HER2/neu-P30 stimulates stronger immunity against HER2/neuexpressing Tg1-1 breast cancer than DC HER2/neu immunization in transgenic FVBneuN mice with HER2/neu self-immune tolerance.
DISCUSSION
P30 (FNNFTVSFWLRVPKVSASHLE) derived from tetanus toxin is a universally potent immunogenic CD4
þ Th epitope. 43 It has been demonstrated that HER2/neu-and OVA-specific DNA vaccines 
enhanced CD4
þ T-cell-stimulated CTL proliferation, thus further supporting our recent finding that DC-primed CD4 þ T cells are able to directly stimulate in vivo CD8 þ CTL responses. 39 The FVBneuN transgenic mice were derived from the parental FVB/NJ strain expressing the wild-type rat HER2/neu cDNA under the control of a MMTV promoter. 44 Because the HER2/neu tumor
FITC-CD44
PE-CD4 antigen is self antigen in transgenic mice, that allows for the development of tolerance to the self HER2/neu antigen, as evidenced by the poor ability of these mice to develop neuspecific antitumor immunity following vaccination as compared with the parental FVB/NJ mice. 45 Therefore, this mouse model closely mimics immune tolerance in HER2/neu-positive breast cancer patients and is suitable for evaluating HER2/neu-targeted vaccines. We previously showed that HER2/neu-specific DC vaccine stimulated more efficient HER2/neu-specific CTL responses and antitumor immunity than DNA vaccine in wildtype FVB/NJ mice. 37, 38 However, it was not successful in stimulating efficient protective antitumor immunity against Tg1-1 tumor cell in transgenic FVBneuN mice mainly because of its inability to break HER2/neu-specific self-immune tolerance. 38 It has been demonstrated that HER2/neu-and OVA-specific DNA vaccines containing P30 epitope can break self-immune tolerance in transgenic MMTV-c-neu and rat insulin promoter-mOVA mice, respectively. 21, 22 In this study, we generated HER2/neu-specific engineered DC HER2/neu-P30 vaccine by transfecting BM-derived DCs with AdV HER2/neu-P30 carrying the mutant HER2/neu DNA containing the potent CD4
þ Th epitope P30, and assessed the stimulatory effect of DC HER2/neu-P30 vaccination on CD8
þ CTL responses and antitumor immunity. We demonstrate that DC HER2/ neu-P30 vaccine expressing the potent P30 epitope is capable of stimulating more efficient CTL responses and protective immunity against the challenge of a larger dose (1 Â To further improve the efficacy of our DC HER2/neu-P30 vaccine, some factors such as the AdV transfection efficiency and the route of vaccination are thought to be critical. For example, an efficient infection of target cells by AdVs requires two predominant viralhost cell receptor interactions. Primary adsorption of AdVs relies on the interaction of the viral knob domain with a cellular surface receptor designated as coxsackievirus and adenovirus receptor (CAR). 46 Subsequently, the interaction of arginine-glycine-aspartic acid motifs on the viral penton base with the cellular aVb3 and aVb5 integrins facilitates AdV entry via clathrin-mediated endocytosis. 47, 48 Although AdVs can infect a wide range of cell types, DCs are not susceptible to AdV infection, in part, because of the absence of CAR expression by DCs, 49, 50 which directly affects the therapeutic effect of engineered DC-based vaccines. Fiber gene modification by insertion of arginine-glycine-aspartic acid sequence in the viral fiber knob's H1 loop has been shown to enhance AdV infection of DCs through binding of arginine-glycineaspartic acid motif to DC integrins leading to enhanced DC-mediated antitumor immunity. 51, 52 In this study, we demonstrate that the expression of transgene HER2/neu is only in o60% of the engineered DCs. To enhance HER2/neu transgene expression, we will construct AdV HER2/neu-P30 with fiber gene arginine-glycine-aspartic acid modification for generation of new DC HER2/neu-P30 with enhanced stimulation of HER2/neu-specific CTL responses and antitumor immunity. Secondly, exogenous DCs injected by i.v. or subcutaneous (s.c.) routes traffic into spleen alone or spleen and draining peripheral lymph nodes, respectively, [53] [54] [55] [56] [57] and induce primary responses localized to these same compartments. 56 It has been demonstrated that s.c. DC immunization induced efficient immunity against s.c. tumors, and about 10-fold more DCs were required for i.v. injection to induce immunity against s.c. tumors, compared with s.c. injection. 57 It has also been demonstrated that lymph node and spleen compartments are responsible for immunity against s.c. and lung tumors, respectively. 56 As we assess antitumor immunity against lung tumor metastasis, we selected the i.v. immunization route in this study. We demonstrate that i.v. vaccination of engineered DC HER2/ neu-P30 stimulates potent immunity against lung metastasis of HER2/neu-expressing Tg1-1 tumors in transgenic FVBneuN mice. We also find that the immunity against lung metastasis of Tg1-1 tumors in transgenic FVBneuN mice with s.c. vaccination of DC HER2/ neu-P30 is much less compared with i.v. immunization of DC HER2/neu-P30 (data not shown). Our data thus confirm the importance of DC vaccination route in induction of immunity against tumors in their specific locations.
We have recently demonstrated that vaccine-stimulated HER2/ neu-specific CTLs are capable of efficiently killing trastuzumabresistant BT474 breast cancer cells in vitro and eradicating BT474 breast cancer in athymic nude mice. 58 Therefore, the engineered DC HER2/neu-P30 vaccine may provide a new immunotherapy option for women with HER2 þ breast cancer, especially for trastuzumabresistant HER2 þ breast cancer patients.
